Human Papillomavirus Genotype
Expected Turnaround Time
3-5 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
The APTIMA HPV 16 18/45 Genotype Assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) of human papillomavirus (HPV) types 16, 18, and 45 in cervical specimens from women with APTIMA HPV Assay positive results. The APTIMA HPV 16 18/45 Genotype Assay can differentiate HPV 16 from HPV 18 and/ or HPV 45, but does not differentiate between HPV 18 and HPV 45.
Requisition Forms
Specimen Requirements
Specimen Requirements
Cervical Cells: 2 mL, ThinPrep® or SurePath™
Specimen Stability
- ThinPrep: 105 days (not above 8°C more than 30 days)
- SurePath: 21 Days
Storage Requirements
2°C to 30°C
Shipping Conditions
Ambient
Specimen Rejection Criteria
Insufficient specimen; Low sample cellularity
Test Details
Keywords
Pathology, Gynecologic cancer, Molecular Diagnostics, Oncology, Women's Health, Genotyping, STI
Test Method
Transcription-Mediated Amplification (TMA)
Methodology Category
Molecular
Regulatory Status
IVD